Laurie Glimcher

Laurie Glimcher
Born1951 (age 74–75)
EducationRadcliffe College (BS)
Harvard University (MD)
Spouse(s)
​
​
(m. 1973, divorced)​

Gregory Petsko
Children3, including Jake Auchincloss
FatherMelvin J. Glimcher
AwardsWilliam B. Coley Award (2012)
Scientific career
FieldsCancer immunotherapy
WorkplacesHarvard Medical School
Dana–Farber Cancer Institute

Laurie Hollis Glimcher (born 1951) is an American physician-scientist and former President and CEO of Dana–Farber Cancer Institute. She was elected a member of the American Philosophical Society in 2019. In October 2024, Glimcher stepped down as President and CEO of Dana-Farber.[1]

Education

Glimcher graduated from the Winsor School, an all-girls private school in Boston, Massachusetts, in 1968.[2] In 1972, she graduated magna cum laude from Radcliffe College, and then graduated cum laude from Harvard Medical School in 1976.[3]

Work

She joined the board of directors of Bristol-Myers Squibb in 1997 and retired from the board in 2017.[4][5][6] In 2017, she joined the board of GlaxoSmithKline. Her research laboratory received funding from Merck & Co for a project focused on developing new therapies for the treatment of osteoporosis in 2008.[7]

From 1991 to 2012, Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, a professor of medicine at Harvard Medical School.[8] Clinically, she is a specialist in osteoporosis.[3][4]

From 2012 to 2016, Glimcher served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs.[9][10]

In February 2016, Laurie Glimcher was named the president and CEO of Dana–Farber Cancer Institute. Glimcher was considered for the position for the Dean of Harvard Medical School but turned the position down in order to become the president of the Dana–Farber Cancer Institute.[11]

At Dana-Farber, Glimcher collaborated on research to find methods of combatting cancer from within the human immune system.[12] The Dana–Farber Cancer Institute is an institution that is affiliated with Harvard, as it currently is one of its teaching hospitals. Glimcher, who was the first female dean of any medical school in New York state, became the first female to lead the Dana–Farber Cancer Institute.[13]

In 2017, she joined the board of GlaxoSmithKline.[14] In 2020, she joined the board of Analog Devices.[15] She has retired from both boards.

In October 2024, Glimcher stepped down as president and CEO of Dana-Farber after eight years as president and CEO, citing her age (73) and the fact that she had successfully steered the Dana-Farber through the COVID crisis and obtained governmental approval of the building of a new, 300-bed, dedicated cancer hospital in collaboration with Beth Israel Deaconess Medical Center.[16][17][18] Under Glimcher’s leadership, the Dana-Farber Cancer Institute’s regional locations grew from four to seven, and there was a 51% growth in patient volume and a 62% increase in grant and industry-funded research support, totaling $450 million in FY23. She also led The Dana-Farber Campaign, the most ambitious fundraising effort in the history of the Institute which will close at the end of September exceeding its original goal and providing critical funds in support of groundbreaking science, innovative new therapies, and institutional initiatives.[19]

In 2025, the Dana-Farber established the Laurie H. Glimcher, MD, Chair, an endowed position honoring her as the Institute’s seventh president and CEO. This endowment "celebrates Glimcher’s significant contributions to cancer science and medicine and ensures the pursuit of innovative and groundbreaking advancements in cancer research. A generous group of Trustees, colleagues, friends, and supporters contributed over $3 million to establish the chair and commemorate Glimcher’s legacy."[20]

Research

Glimcher's research has focused on the molecular regulation of immunity and the interface between immune function and other tissues (notably bone and liver).[21][22][23]

Transcriptional control of lymphocyte differentiation

Glimcher contributed to the identification of NK1.1, an alloantigen that became an important marker for NK and NKT cell populations.[24][25]

Glimcher's laboratory discovered T-bet (TBX21) in 2000. T-bet was identified as a T-box transcription factor selectively associated with TH1 differentiation and shown to activate IFN-γ expression while repressing the opposing TH2 cytokine program. Ectopic expression of T-bet could redirect polarized TH2 and TC2 cells toward TH1- and TC1-like phenotypes, respectively.[26]

Subsequent work demonstrated that T-bet has functions extending beyond CD4 T-cell differentiation. It regulates type 1 immune responses in multiple adaptive and innate immune populations, including CD8 T cells, NKT cells, B cells, NK cells and dendritic cells.[27]

T-bet was also implicated in inflammatory disease. Mice lacking T-bet developed spontaneous airway inflammation and physiological changes resembling features of human asthma, supporting a role for T-bet in regulating airway inflammatory responses.[28] Variants in the human TBX21 locus were subsequently associated with asthma and airway hyperresponsiveness, although the authors noted that further studies were needed to establish the generality of these associations.[29]

In intestinal inflammation, Glimcher and colleagues showed that T-bet deficiency in the innate immune system caused spontaneous, transmissible ulcerative colitis. The phenotype involved altered dendritic-cell cytokine production and changes in the intestinal microbial community, linking T-bet-dependent transcriptional regulation to host–microbiota homeostasis.[30]

Glimcher laboratory investigated the atypical kinase RIOK2 in hematopoietic differentiation. Loss of Riok2 in mice caused anemia and myeloproliferation, while increased IL-22 signaling contributed to impaired erythropoiesis; blocking IL-22 signaling alleviated the erythroid defect.[31]

In human hematopoietic stem and progenitor cells, RIOK2 was subsequently identified as a transcriptional regulator of lineage commitment. It promotes erythroid differentiation while suppressing megakaryocytic and myeloid differentiation, in part through regulation of key hematopoietic transcription factors including GATA1, GATA2, SPI1, RUNX3 and KLF1.[32]

XBP1 and the unfolded protein response

Glimcher's laboratory helped establish the role of the transcription factor XBP1 in secretory-cell differentiation and metabolism. Her group showed that XBP1 is required for plasma cell differentiation and for the expansion of the endoplasmic reticulum and secretory machinery needed for sustained immunoglobulin production.[33][34]

The laboratory subsequently showed that XBP1 also has a metabolic function in the liver, where it is induced by dietary carbohydrates and promotes expression of genes involved in de novo fatty-acid synthesis. Liver-specific deletion of XBP1 reduced hepatic lipid production and caused marked hypocholesterolemia and hypotriglyceridemia.[35]

More recent work from Glimcher and colleagues has extended the IRE1α–XBP1 pathway to innate lymphocyte biology. IRE1α and XBP1 promote the expansion and effector function of NK cells, including responses to viral infection and tumors, through an IRE1α–XBP1–c-Myc axis that also supports oxidative phosphorylation.[36]

Osteobiology: Schnurri-3 and bone-mass regulation

Glimcher's laboratory identified Schnurri-3 as an important regulator of adult bone formation. Mice lacking Shn3 develop increased bone mass and osteosclerosis because of enhanced osteoblast activity; SHN3 promotes degradation of RUNX2, a major regulator of osteoblast differentiation.[37]

Subsequent studies showed that SHN3 acts as a negative regulator of ERK signaling downstream of WNT in osteoblasts. Inducible reduction of SHN3 in adult mice increased bone mass, providing preclinical evidence that the SHN3 pathway could be targeted to enhance bone formation.[38]

Metabolism, endoplasmic-reticulum stress and disease

Glimcher's work on XBP1 helped establish a mechanistic connection between the unfolded protein response, cellular secretory capacity and metabolism. In particular, the discovery that XBP1 regulates hepatic lipogenesis expanded the known functions of UPR transcription factors beyond proteostasis and provided a framework for studying their involvement in metabolic disease.[39]

Cancer immunology and translational research

Glimcher's later work has increasingly examined transcriptional and stress-response pathways that regulate immune-cell function in cancer. Her group's studies of the IRE1α–XBP1 pathway demonstrated that endoplasmic-reticulum stress signaling can influence NK-cell proliferation, metabolism and anti-tumor responses.[40][41]

In 2026, Glimcher and colleagues reported that salt-inducible kinases SIK2 and SIK3 promote T-cell dysfunction in the immunosuppressive microenvironment of high-grade serous ovarian carcinoma. Human T cells exposed to patient ascites expressed high levels of SIK2, SIK3 and the upstream kinase LKB1, while pharmacological or genetic inhibition of SIK2/3 enhanced T-cell effector responses.[42]

In mouse models of resistant ovarian cancer, genetic ablation or pharmacological inhibition of SIKs reduced disease progression and improved survival, while combining SIK inhibition with PD-1 checkpoint blockade produced an additional survival benefit. Mechanistically, T-cell-intrinsic SIK2/3 signaling promoted immunosuppression in part through TXNIP induction and suppression of LYST, whereas SIK inhibition increased T-cell infiltration, cytotoxicity and IFN-γ production and shifted the tumor microenvironment toward an immunostimulatory state.[43]

These findings identify SIK2 and SIK3 as potential therapeutic targets for overcoming T-cell immunosuppression in ovarian cancer and provide preclinical support for SIK inhibition as an immunotherapeutic strategy.[44]

Awards and memberships

Glimcher received the L'Oréal-UNESCO Awards for Women in Science in 2014 for her work in the field of immunology and her research regarding the control of immune responses.[45][41] In 2014, she received the Margaret Kripke Legend Award.[46] She received the Steven C. Beering Award in 2015.[47] In 2018, she received the American Association of Immunologists Lifetime Achievement Award.[48]

She has been elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. She is a member of American Academy of Arts and Sciences, American Association of Immunologists, American Society for Clinical Investigation, American Association of Physicians, and American Association for the Advancement of Science.[9] She was the president of the American Association of Immunologists from 2003 to 2004.[49]

In 2020 she was named the newest member of the Stand Up to Cancer Scientific Advisory Committee.[50]

Media

In 2015, Glimcher was targeted by animal rights activists over their protest of withdrawal of support for chimpanzees in Liberia by the New York Blood Center where Glimcher had been on the board for two years.[51][52][53]

Glimcher's dual role as Dana-Farber CEO and director of multiple corporate boards was highlighted in a The Boston Globe Spotlight article [54] and resulted in calls from some Harvard physicians and Boston hospital staff for the prohibition of hospital executives from serving on corporate boards.[55]

In January 2024, Glimcher was among four researchers at Dana-Farber accused of manipulating data in research papers to mislead readers.[56][57][58]

Family

Glimcher is the daughter of Geraldine Lee (Bogolub) and Melvin J. Glimcher, who was a pioneer in the development of artificial limbs while the chair of the Massachusetts General Hospital Orthopedics Department. Her family is Jewish.[59]

Glimcher followed in the footsteps of her father by later becoming a full professor at Harvard Medical School at the age of 39; the two became research partners.[12]

Glimcher was married to Hugh Auchincloss,[60] who was the top deputy to Dr. Anthony Fauci,[61] and prior to that was a chief of transplant surgery at Brigham & Women's Hospital,[62] They had three children, Kalah, Hugh and Jake Auchincloss.[63]

She is currently married to Gregory Petsko, Professor of Neurology in the Ann Romney Center for Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital, who was director of the Rosenstiel Basic Medical Sciences Research Center and chair of biochemistry at Brandeis University prior to moving to Weill Cornell Medicine, where he became director of the Helen and Robert Appel Alzheimer's Disease Research Institute.[64] On October 24, 2023 he was awarded the National Medal of Science by President Joe Biden; the National Medal of Science is the nation’s highest scientific honor.[65]

Her daughter, Kalah Auchincloss is the Co-Founder and President of Canal Row Advisors, which helps companies navigate the FDA's complexities.[66] Before that she was a senior vice president of regulatory compliance and deputy general counsel for Greenleaf Health and previously was deputy chief of staff for two Food and Drug Administration commissioners.[67] Her eldest son, Hugh Glimcher Auchincloss, is a thoracic surgeon at Massachusetts General Hospital.[68] Her younger son, Jake Auchincloss, is a United State Congressman, the Representative for Massachusetts's 4th Congressional District.[61][69][70]

See also

References

  1. ↑ "Laurie H. Glimcher, MD, named president of Dana–Farber Cancer Institute – Dana–Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved October 11, 2016.
  2. ↑ "Laurie Glimcher '68". Winsor School. December 2, 2019. Retrieved March 26, 2020.
  3. 1 2 "Laurie H. Glimcher, MD - Dana–Farber Cancer Institute | Boston, MA". www.dana-farber.org. Retrieved March 26, 2020.
  4. 1 2 Hartocollis, Anemona (September 7, 2011). "Harvard Researcher Chosen as New Dean of Weill Cornell Medical College". The New York Times. Retrieved September 9, 2011.
  5. ↑ "New Dean of Weill Cornell Medical College Calls for Stronger Ties to Industry". Chronicle of Higher Education. September 8, 2011. Retrieved September 9, 2011.
  6. ↑ "BRIEF-Bristol-Myers Squibb Co says Laurie Glimcher notified co that she will retire from board". Retrieved October 16, 2017.
  7. ↑ "Harvard Announces Pioneering Collaboration with Merck & Co., Inc. to Advance Osteoporosis Research". Retrieved October 16, 2017.
  8. ↑ official p. at Harvard
  9. 1 2 "Bristol-Myers Squibb: Laurie H. Glimcher, M.D." www.bms.com. Retrieved December 8, 2016.
  10. ↑ Hartocollis, Anemona (September 7, 2011). "Laurie H. Glimcher Named Dean of Weill Cornell Medical College". The New York Times. ISSN 0362-4331. Retrieved October 11, 2016.
  11. ↑ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. March 1, 2016. Retrieved December 8, 2016.
  12. 1 2 Bailey, Melissa (March 2016). "Recruited to lead Harvard Med, 'fearless' scientist chose Dana-Farber". Stat News. Retrieved April 26, 2017.
  13. ↑ "Laurie Glimcher". The Forum at Harvard T. H. Chan School of Public Health. January 17, 2019. Retrieved November 3, 2020.
  14. ↑ "Cancer expert joins the overhaul at Glaxo - The Times". The Times. July 22, 2017. Retrieved July 21, 2021.
  15. ↑ "Dana-Farber CEO joining Analog board - The Boston Globe". BostonGlobe.com. August 18, 2020. Retrieved November 17, 2020.
  16. ↑ "Boston needs its own cancer center. Dana-Farber, BIDMC will create it. - The Boston Globe". BostonGlobe.com. Retrieved June 23, 2026.
  17. ↑ Globe, Shirley Leung-The Boston (September 6, 2024). "Dana-Farber's Laurie Glimcher is leaving on her own terms. That's the difference between male and female leadership". STAT. Retrieved June 23, 2026.
  18. ↑ Globe, Shirley Leung-The Boston (December 11, 2023). "Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker". STAT. Retrieved June 23, 2026.
  19. ↑ "Dana-Farber President and CEO Laurie Glimcher, MD, announces her plans to step down capping a highly successful tenure marked with discovery and innovation | Dana-Farber Cancer Institute". www.dana-farber.org. Retrieved June 23, 2026.
  20. ↑ Dougherty, Lori (March 25, 2025). "Laurie H. Glimcher, MD, honored with endowed chair". Impact Magazine. Retrieved June 23, 2026.
  21. ↑ Jones, Dallas C.; Wein, Marc N.; Glimcher, Laurie H. (January 1, 2007). "Schnurri-3: A Key Regulator of Postnatal Skeletal Remodeling". In Choi, Yongwon (ed.). Osteoimmunology. Advances in Experimental Medicine and Biology. Vol. 602. Springer US. pp. 1–13. doi:10.1007/978-0-387-72009-8_1. ISBN 9780387720081. PMID 17966382.
  22. ↑ Neill, US (July 1, 2016). "A conversation with Laurie Glimcher". The Journal of Clinical Investigation. 126 (7): 2392–3. doi:10.1172/jci88964. PMC 4922720. PMID 27367182.
  23. ↑ Sedwick, Caitlin (April 19, 2010). "Laurie Glimcher: Merging cell biology and immune function". The Journal of Cell Biology. 189 (2): 192–193. doi:10.1083/jcb.1892pi. PMC 2856904. PMID 20404104.
  24. ↑ Glimcher, Laurie H. (2010). "Laurie Glimcher: Merging cell biology and immune function". Journal of Clinical Investigation. doi:10.1172/JCI42156.
  25. ↑ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. March 1, 2016. Retrieved October 11, 2016.
  26. ↑ Szabo, Susanne J.; Kim, Sean T.; Costa, Gina L.; Zhang, Xiankui; Fathman, C. Garrison; Glimcher, Laurie H. (2000). "A novel transcription factor, T-bet, directs Th1 lineage commitment". Cell. 100 (6): 655–669. doi:10.1016/S0092-8674(00)80702-3.
  27. ↑ Lazarevic, Vanja; Glimcher, Laurie H.; Lord, Graham M. (2013). "T-bet: a bridge between innate and adaptive immunity". Nature Reviews Immunology. 13: 777–789. doi:10.1038/nri3536.
  28. ↑ Finotto, Susetta; Neurath, Markus F.; Glickman, Jonathan N. (2002). "Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet". Science. 295 (5553): 336–338. doi:10.1126/science.1065544.
  29. ↑ Raby, Benjamin A.; Hwang, Eun-Sook; Van Steen, Kristel (2006). "T-bet polymorphisms are associated with asthma and airway hyperresponsiveness". American Journal of Respiratory and Critical Care Medicine. 173 (1): 64–70. doi:10.1164/rccm.200503-505OC.
  30. ↑ Garrett, Wendy S.; Lord, Graham M.; Punit, Shivesh (2007). "Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system". Cell. 131 (1): 33–45. doi:10.1016/j.cell.2007.08.017.
  31. ↑ Raundhal, Mahesh; Ghosh, Shrestha; Myers, Samuel A. (2021). "Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias". Nature Immunology. 22 (4): 520–529. doi:10.1038/s41590-021-00895-4.
  32. ↑ Ghosh, Shrestha; Raundhal, Mahesh; Myers, Samuel A. (2022). "Identification of RIOK2 as a master regulator of human blood cell development". Nature Immunology. 23 (1): 109–121. doi:10.1038/s41590-021-01079-w.
  33. ↑ Reimold, Ann M.; Iwakoshi, Neal N.; Manis, John (2001). "Plasma cell differentiation requires the transcription factor XBP-1". Nature. 412 (6844): 300–307. doi:10.1038/35085509.
  34. ↑ Tirosh, Boaz; Iwakoshi, Neal N.; Glimcher, Laurie H. (2005). "XBP-1 specifically promotes IgM synthesis and secretion, but is dispensable for degradation of glycoproteins in primary B cells". Journal of Experimental Medicine. 202 (6): 769–779. doi:10.1084/jem.20050575.
  35. ↑ Lee, Ann-Hwee; Scapa, Erez F.; Cohen, David E.; Glimcher, Laurie H. (2008). "Regulation of hepatic lipogenesis by the transcription factor XBP1". Science. 320 (5882): 1492–1496. doi:10.1126/science.1158042.
  36. ↑ Dong, Han; Adams, N. M.; Xu, Yichi (2021). "The IRE1 ER stress sensor activates natural killer cell immunity by regulating c-Myc". Cancer Immunology Research.
  37. ↑ Jones, Dallas C.; Wein, Marc N.; Oukka, Mohamed (2006). "Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3". Science. 312 (5777): 1223–1227. doi:10.1126/science.1126313.
  38. ↑ Shim, Jae-Hyuck; Greenblatt, Matthew B.; Zou, Weiguo (2013). "Schnurri-3 regulates ERK downstream of WNT signaling in osteoblasts". Journal of Clinical Investigation. 123 (9): 4010–4022. doi:10.1172/JCI69443.
  39. ↑ Lee, Ann-Hwee; Scapa, Erez F.; Cohen, David E.; Glimcher, Laurie H. (2008). "Regulation of hepatic lipogenesis by the transcription factor XBP1". Science. 320 (5882): 1492–1496. doi:10.1126/science.1158042.
  40. ↑ Dong, Han; Adams, N. M.; Xu, Yichi (2021). "The IRE1 ER stress sensor activates natural killer cell immunity by regulating c-Myc". Cancer Immunology Research.
  41. 1 2 Sedwick, Caitlin (April 19, 2010). "Laurie Glimcher: Merging cell biology and immune function". The Journal of Cell Biology. 189 (2): 192–193. doi:10.1083/jcb.1892pi. PMC 2856904. PMID 20404104.
  42. ↑ Dong, Han; Ray, Arindam; Rotter, Lara; Wang, Jinhua; Grabski, Isabella; Glimcher, Laurie H. (2026). "Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer". Nature Immunology.
  43. ↑ Dong, Han; Ray, Arindam; Rotter, Lara (2026). "Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer". Nature Immunology.
  44. ↑ Dong, Han; Ray, Arindam; Rotter, Lara (2026). "Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer". Nature Immunology.
  45. ↑ 16th Annual L’Oréal-UNESCO Awards for Women in Science - 2014
  46. ↑ "Margaret L. Kripke Legend Award". M. D. Anderson Cancer Center. Retrieved February 19, 2022.
  47. ↑ "Steven C. Beering Award | Office of Faculty Affairs and Professional Development". Archived from the original on July 11, 2018. Retrieved July 26, 2018.
  48. ↑ "Past Recipients". The American Association of Immunologists. Retrieved September 19, 2018.
  49. ↑ "Laurie Glimcher '68". Winsor School. December 2, 2019. Retrieved November 3, 2020.
  50. ↑ "Dr. Laurie Glimcher Named to Stand Up To Cancer Scientific Advisory Committee". Stand Up To Cancer. Archived from the original on November 10, 2020. Retrieved November 3, 2020.
  51. ↑ "Weill Cornell Medicine Dean Accused of Chimp Abandonment". The Cornell Daily Sun. October 30, 2015. Retrieved October 11, 2016.
  52. ↑ "Resolution at Last for New York Blood Center Chimps in Liberia". Jane Goodall's Good for All News. May 31, 2017. Retrieved June 28, 2026.
  53. ↑ Gorman, James (May 30, 2017). "New York Blood Center Reaches a Deal to Help Care for Research Chimps". The New York Times. ISSN 0362-4331. Retrieved June 28, 2026.
  54. ↑ Kowalczyk, Liz; Ryley, Spotlight fellow Sarah L.; Arsenault, Mark (April 3, 2021). "Boston's hospital chiefs moonlight on corporate boards at rates far beyond the national level". The Boston Globe. Retrieved August 8, 2021.
  55. ↑ Kowalczyk, Liz (August 7, 2021). "A group of doctors, medical students seeks to prohibit Boston's hospital chiefs from working on corporate boards". The Boston Globe. Retrieved August 8, 2021.
  56. ↑ Mueller, Benjamin (January 22, 2024). "Dana‑Farber Cancer Center Seeks to Retract Flawed Studies". The New York Times. Archived from the original on July 11, 2025. Retrieved January 26, 2024.
  57. ↑ Paulus, Veronica H. (January 12, 2024). "Dana‑Farber Cancer Institute Researchers Accused of Manipulating Data". The Harvard Crimson. Archived from the original on April 10, 2025. Retrieved January 23, 2024.
  58. ↑ Paulus, Veronica H. (January 22, 2024). "Dana‑Farber Cancer Institute Issues Corrections to Research Records". The Harvard Crimson. Archived from the original on June 22, 2025. Retrieved January 23, 2024.
  59. ↑ "Israel".
  60. ↑ "Hugh Auchincloss Jr. Weds Laurie Glimcher". The New York Times. August 27, 1973. Retrieved April 24, 2020.
  61. 1 2 DeCosta-Clipa, Nik (July 31, 2020). "Jake Auchincloss suggests he's the frontrunner to replace Joe Kennedy. His opponents are certainly treating him like one". Boston.com. Retrieved August 1, 2020.
  62. ↑ "Glimcher Helps Women Balance Career, family". Archived from the original on October 16, 2017. Retrieved October 16, 2017.
  63. ↑ "Science is in the bones for dad, daughter". Archived from the original on April 1, 2017. Retrieved October 16, 2017.
  64. ↑ Hartocollis, Anemona (September 7, 2011). "Harvard Researcher Chosen as New Dean of Weill Cornell Medical College". New York Times. Retrieved April 26, 2017.
  65. ↑ House, The White (October 24, 2023). "President Biden Honors Leading American Scientists, Technologists, and Innovators". The White House. Retrieved June 23, 2026.
  66. ↑ "Canal Row Advisors | FDA fluency at every critical turn". Canal Row. Retrieved June 23, 2026.
  67. ↑ "Kalah Auchincloss Joins Greenleaf Health as SVP". Retrieved October 16, 2017.
  68. ↑ "Recruited to lead Harvard med, 'fearless' scientist chose Dana-Farber". STAT. March 1, 2016. Retrieved October 16, 2017.
  69. ↑ "Ex-Marine Jake Auchincloss wins crowded Democratic primary in race to fill House seat being vacated by Joe Kennedy III". AP NEWS. September 4, 2020. Retrieved September 8, 2020.
  70. ↑ Phillips, Lucas (January 3, 2021). "Auchincloss sworn in as Massachusetts' newest US House member". The Boston Globe. Retrieved January 4, 2021.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.